The vaccine’s last mile problem

Source: This post is based on the article “The vaccine’s last-mile problem” published in The Hindu on 31st August 2021. Relevance: Universalisation of vaccination programme. Synopsis: In vaccination programmes, which have complex delivery requirements, the last mile means to make or break. Context The article highlights the problem of increased inequalities in vaccination, which have… Continue reading The vaccine’s last mile problem

Gennova’s mRNA vaccine gets clearance for Phase 2/3 clinical trials

Source: PIB Contents1 What is the News?2 About HGCO19 Vaccine:3 About mRNA Vaccines:4 Benefits of mRNA Vaccines:5 Disadvantages of mRNA Vaccines: What is the News? India’s first mRNA vaccine against coronavirus named “HGCO19” has been found to be safe and has been given the go-ahead from the Drugs Controller General of India (DCGI) to move… Continue reading Gennova’s mRNA vaccine gets clearance for Phase 2/3 clinical trials

Zydus Cadila vaccine gets emergency nod

Source: Livemint, The Hindu, PIB, Business Standard What is the News? Drugs Controller General of India’s (DCGI’s) has granted emergency approval for Zycov-D vaccine. About Zycov-D: Zycov-D is a DNA plasmid-based Covid-19 vaccine developed by Zycov Cadilla Group in partnership with the Department of Biotechnology under the ‘Mission COVID Suraksha’. It is the world’s first… Continue reading Zydus Cadila vaccine gets emergency nod

We’ve successfully made Covid vaccines. Now, India must focus on drug development

Source: Indian Express Relevance: Issues related to the development and production of new antibiotics Synopsis: Efforts should be initiated to consolidate existing strengths in pharmaceuticals and support the country’s antibiotic needs Challenges posed by AMR India has one of the highest levels of antibiotic resistance. It complicates not only the treatment of life-threatening infections, but… Continue reading We’ve successfully made Covid vaccines. Now, India must focus on drug development

First Nasal Vaccine Developed by Bharat Biotech supported by DBT-BIRAC gets nod of regulator for Phase 2 Trial

Source: PIB Contents1 What is the News?2 About BBV154:3 About Mission COVID Suraksha 4 About BIRAC What is the News? BBV154, the first Nasal Vaccine against Covid-19 has received the regulator’s nod for conducting Phase 2 and 3 clinical trials. About BBV154: BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine. It is the first… Continue reading First Nasal Vaccine Developed by Bharat Biotech supported by DBT-BIRAC gets nod of regulator for Phase 2 Trial

All WHO-approved jabs must be recognised for travel: UN

Source: The Hindu Relevance: Vaccination is essential for global economic recovery. The World Health Organization recently said that any COVID-19 vaccine it has authorised for emergency use should be recognised by countries as they open up their borders to inoculated travelers. The move could force Western countries to broaden their acceptance of two apparently less… Continue reading All WHO-approved jabs must be recognised for travel: UN

Vaccine battle among countries 

Source: Click here Syllabus: GS 2 – Health related issues Synopsis: Countries should refrain from engaging in vaccine battles and focus on global cooperation. Introduction  Almost all countries across the globe are in need of access to vaccines. But the developed countries are mindlessly collecting approved vaccines. Only the countries in the global south like… Continue reading Vaccine battle among countries 

Explained: What’s at stake in India’s biggest ever trial of tuberculosis vaccines

Recently,the Indian Council of Medical Research(ICMR) has launched India’s first large-scale trial for two new tuberculosis(TB) vaccines. The two vaccines being tested in the trial are (a)Immuvac which is also known as mycobacterium indicus pranii or MIP and (b)VPM1002. Currently,Bacille Calmette-Guerin(BCG) vaccine is used in the routine Expanded Programme of Immunisation(EPI) in countries across the… Continue reading Explained: What’s at stake in India’s biggest ever trial of tuberculosis vaccines

Blog
Academy
Community